Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02145039

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.

Status: 
Recruiting
Study Date: 
Wed, 10/01/2014 to Mon, 06/01/2020
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Fludarabine Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant. Other Name: Fludara Drug: Cyclophosphamide Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant. Radiation: Total Body Irradiation TBI 200cGy on day -1 before transplant. Other Name: TBI Biological: Haploidentical stem cell transplant Non-T-cell depleted bone marrow infusion Other Name: HSCT